Invenomic

With an average five-year Morningstar Rating of 5.0 stars across its open-end and exchange-traded products, the firm has demonstrated its ability to deploy capital successfully for investors. Invenomic has undergone a bout of turnover in the past five years, as seen in its lower-than-average portfolio manager retention. This is a concern, as long-term stability tends to support positive results. Lofty fees for the firm's open-end and exchange-traded funds are a weakness, contributing negatively to Invenomic's rating and creating a larger performance hurdle. The firm's fund fees, on average, fall within the second most-expensive quintile of similarly distributed strategies.